Compositions and methods for identification of chromosomal microdeletions

Patent metadata

Field	Value
Publication number	US-2025388956-A1
Application number	US-202318877708-A
Country	US
Kind code	A1
Filing date	Jun 28, 2023
Priority date	Jun 29, 2022
Publication date	Dec 25, 2025
Grant date	—

Abstract

Provided herein are compositions to be used as a positive control for detection of one or more microdeletions of interest in a sample. The positive control can be used to determine an error and an efficiency rate for assays used to identify microdeletions such as 22q1 1.2 deletion (DiGeorge syndrome), chromosome 5p15.2 (Cri-du-chat), 1p36 deletion, 15q1 1.2˜q13 deletion (Prader-Willi syndrome), and/or 15q1 1˜q13 (Angelman syndrome).

First claim

What is claimed is:

1 . A composition comprising an engineered nucleic acid construct for use as a positive control for one or more primers targeting one or more microdeletions of interest in a sample, wherein the construct is engineered from a reference nucleic acid sequence comprising a microdeletion of interest, wherein the construct comprises a 5′ end region, a central region, and a 3′ end region, wherein the 5′ end region and 3′ end region comprise reference sequences flanking the microdeletion of interest, wherein the central region of the construct is a DNA barcode, and wherein the DNA barcode replaces the microdeletion sequence of the reference nucleic acid sequence.

2 . The composition of claim 1 , wherein the microdeletion of interest corresponds to 22q11.2 deletion, 5p15.2 deletion, 1p36 deletion, 15q11.2-q13 deletion, or 15q11-q13 deletion.

3 . The composition of claim 1 , wherein the composition comprises (i) a first engineered nucleic acid construct comprising a barcode replacing a microdeletion of interest corresponding to 22q11.2 deletion, (ii) a second engineered nucleic acid construct comprising a barcode replacing a microdeletion of interest corresponding to 5p15.2 deletion, (iii) a third engineered nucleic acid construct comprising a barcode replacing a microdeletion of interest corresponding to 1p36 deletion, (iv) a fourth engineered nucleic acid construct comprising a barcode replacing a microdeletion of interest corresponding to 15q11.2-q13 deletion, and (v) a fifth engineered nucleic acid construct comprising a barcode replacing a microdeletion of interest corresponding to 15q11-q13 deletion.

4 . The composition of claim 1 , wherein the microdeletion of interest is associated with a cancer.

5 . The composition of claim 1 , wherein the barcode is from about 6 base pairs to about 9 base pairs.

6 . The composition of claim 1 , wherein the 5′ and 3′ end regions of the construct comprise at least one single nucleotide polymorphism (SNP) of interest.

7 . The composition of claim 1 , wherein the 5′ and 3′ end regions of the construct comprise sequences recognized by primers that target a SNP within or flanking the microdeletion of interest.

8 . The composition of claim 3 , wherein the reference nucleic acid sequence is maternal DNA, and wherein the SNP of interest is changed to allow the construct to act as the positive control for a child DNA.

9 . The composition of claim 1 , wherein the size of the construct is from about 100 bp to about 200 bp, or from about 160 bp to about 200 bp.

10 . A method of preparing the construct for use as a positive control for one or more primers targeting one or more microdeletions of interest in a sample according to claims 1-9 , wherein the method comprises obtaining a reference nucleic acid; isolating a nucleic acid sequence comprising a 5′ end and 3′ end flanks a microdeletion of interest; and replacing the central region of the reference nucleic acid sequence corresponding to the microdeletion of interest with a barcode.

11 . The method of claim 10 , wherein the preparing a construct for use as a positive control for one or more primers targeting one or more microdeletions is performed by chemical synthesis of the construct and subsequent PCR amplification of the synthesized construct.

12 . The method of claim 10 , wherein the sample is a plasma sample and comprises cell-free DNA.

13 . The method of claim 10 , wherein the sample comprises circulating tumor DNA (ctDNA).

14 . The method of claim 10 , wherein the sample comprises cells and/or tissues.

15 . The method of claim 10 , wherein the reference nucleic acid is obtained from a cell line suitable for use as a positive control for detecting the one or more microdeletions.

16 . The method of claim 10 , wherein the reference nucleic acid is genomic DNA.

17 . The method of claim 10 , wherein the reference nucleic acid is mono-nucleosomal.

18 . A method of preparing a preparation of amplified DNA derived from a sample or a fraction thereof useful for identifying one or more microdeletions associated with a disease or disorder, comprising:
(a) preparing a construct for use as a positive control for detection of one or more microdeletions according to claims 10 - 17 ; (b) adding the construct from (a) into the sample or fraction thereof to obtain a spiked sample and extracting nucleic acids from the spiked sample or fraction thereof; (c) performing targeted amplification on the spiked sample or fractions thereof from (b) to amplify one or more target regions comprising microdeletions of interests to obtain amplicons; and (d) analyzing the amplicons or portions thereof from (c) to determine (i) whether the amplicons comprises the amplified construct as a positive control, and (ii) whether the amplicons comprises the one or more microdeletions of interest.

19 . The method of claim 18 , wherein the sample is a plasma sample and comprises cell-free DNA.

20 . The method of claim 19 , wherein the plasma sample comprises maternal and fetal cell-free DNA, and wherein a SNP in the construct is changed to act as a positive control for the fetal cell-free DNA.

21 . The method of claim 20 , wherein at least 5 microdeletions of interest are amplified in a single reaction volume, and wherein a construct for use as a positive control is prepared for each of the at least 5 microdeletions of interest.

22 . The method of claims 18-21 , wherein the one or more microdeletions comprise 22q11.2 deletion (DiGeorge syndrome), chromosome 5p15.2 (Cri-du-chat), 1p36 deletion, 15q11.2˜q13 deletion (Prader-Willi syndrome), and/or 15q11˜q13 (Angelman syndrome).

23 . The method of claims 18-21 , wherein the one or more microdeletions are associated with a cancer.

24 . The method of claim 18 , further comprising sequencing to detect (i) the presence of the construct as a positive control, and (ii) the presence of the one or more microdeletions of interest.

25 . The method of claim 18 , wherein an efficiency and an error rate is determined for each amplification reaction by using the positive control, wherein the efficiency and the error rate is used to determine the presence of the one or more microdeletions of interest.

26 . The method of claim 18 , wherein an amount of the construct to be added to the sample is determined by (a) mixing DNA from normal female cell line and the construct in a range of proportions to generate a titration series to determine the Limit of Detection; (b) adding the mixture from (a) to DNA depleted plasma; (c) perform targeted amplification of the microdeletion that the construct is positive control for; and (d) determination of the proportion of the construct and the mono-nucleosomal DNA from the normal cell line that allows detection of the construct.

27 . The method of claim 26 , wherein the DNA is mono-nucleosomal DNA.

28 . The method of claim 18 , wherein the sample is a plasma sample from a mother.

29 . A method of preparing a sample comprising nucleic acids, comprising spiking a sample with the composition according to claims 1-9 .

30 . The method according to claim 29 , wherein the sample is a plasma sample from a mother.

31 . The method of any one of claims 18-30 , wherein detection of SNPs flanking the barcodes that replace the microdeletio

Assignees

• Natera Inc

Inventors

• Pawar Hemant
• Xu Wenbo
• Keen-Kim Dianne
• Brevnov Maxim

Classifications

• C12Y207/07

  Nucleotidyltransferases (2.7.7) · CPC title

• C12Q2600/166

  Oligonucleotides used as internal standards, controls or normalisation probes · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6869

  Methods for sequencing · CPC title